Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gilead Sciences to Acquire Arcellx for $7.8B – Bolsters CAR‑T Pipeline with BCMA‑Targeted Anito‑cel

Fineline Cube Feb 24, 2026
Company Deals

Findcure Bio Raises $14.5 Million Series B to Advance Radiopharmaceutical Platform

Fineline Cube Feb 14, 2026
Company Deals

Siemens Healthineers Deepens Mayo Clinic Partnership on AI Neurology and Precision Oncology

Fineline Cube Feb 14, 2026
Company Deals

VivaVision Biotech Files Hong Kong IPO to Advance Ophthalmology Pipeline

Fineline Cube Feb 14, 2026
Company Deals

Genhouse Bio Partners with Gilead on $1.5 Billion Synthetic Lethal Cancer Project GH31

Fineline Cube Feb 14, 2026
Policy / Regulatory

FDA Issues Draft Guidance on Plausible Mechanism Framework – Accelerates Approval Pathway for Individualized Genetic Therapies

Fineline Cube Feb 24, 2026
Company Drug

Sichuan Biokin’s Iza‑Bren Hits PFS and OS Endpoints in Phase III TNBC Study – First Bispecific ADC to Show Dual Survival Benefit

Fineline Cube Feb 24, 2026
Company Drug

Sino Biopharma’s Benmelstobart Secures Fourth NMPA Approval for Stage III NSCLC – Expanding PD‑L1 Franchise in China

Fineline Cube Feb 14, 2026
Company Deals

Sinopharm’s InnoStar Bio-tech Becomes First Pharma Company to IPO on STAR in 2024

Fineline Cube Sep 3, 2024

SHANGHAI—Shanghai InnoStar Bio-tech Co., Ltd., a subsidiary of Sinopharm’s China State Institute of Pharmaceutical Industry...

Company Drug

China’s Evopoint Biosciences and UK’s GSK Eye Breakthrough Therapy Designations for Cancer Therapies

Fineline Cube Sep 3, 2024

BEIJING/LONDON—The Center for Drug Evaluation (CDE) in China has indicated that Evopoint Biosciences’ EZH2 inhibitor...

Company Deals

Duality Biotherapeutics Eyes Hong Kong IPO, Bolstering ADC Pipeline and Global Clinical Trials

Fineline Cube Sep 3, 2024

HONG KONG—Duality Biologics, Inc., a Chinese biotechnology company specializing in antibody drug conjugates (ADCs), is...

Company

MicuRx Pharmaceuticals Reports 44% Revenue Growth and Increased R&D Spending in 2024 H1

Fineline Cube Sep 3, 2024

SHANGHAI—MicuRx Pharmaceuticals (SHA: 688373), a Shanghai-based developer of antibacterial drugs, has released its financial report...

Company Drug

Shandong Buchang Pharmaceuticals’ rhEPO-Fc for CKD Anemia Accepted for Review by China’s CDE

Fineline Cube Sep 3, 2024

BEIJING—The Center for Drug Evaluation (CDE) in China has accepted the market filing for a...

Company Drug

Biocon Biologics Resolves Patent Dispute with J&J, Secures Market Entry for Biosimilar Stelara

Fineline Cube Sep 2, 2024

Biocon Biologics Ltd, the biosimilars division of Indian pharmaceutical company Biocon Ltd (BOM: 532523, NSE:...

Company Drug

Zuellig Pharma Partners with Regeneron for Libtayo Launch in South Korea and Taiwan

Fineline Cube Sep 2, 2024

Singapore-headquartered Zuellig Pharma, a leading healthcare solutions provider, has entered into an agreement with US...

Company Drug

HutchMed Halts China Filing for Gastric Cancer Drug Fruquintinib Following Regulatory Feedback

Fineline Cube Sep 2, 2024

HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013), a China-based biopharmaceutical company, has announced the withdrawal...

Company Drug

Novo Nordisk to Resubmit Wegovy Heart Failure Application with Updated Clinical Data

Fineline Cube Sep 2, 2024

Denmark’s pharmaceutical giant, Novo Nordisk (NYSE: NVO), has reported significant findings on the efficacy of...

Company Drug

AccurEdit Therapeutics’ Gene-Editing Drug ART001 Clears FDA Hurdle for US Clinical Trials

Fineline Cube Sep 2, 2024

SUZHOU—AccurEdit Therapeutics (Suzhou) Co., Ltd, a leading Chinese specialist in gene editing therapies, has announced...

Company Deals

Hybio Pharmaceutical Inks Licensing Deal with Mullan Pharmaceutical for Liraglutide Biosimilar

Fineline Cube Sep 2, 2024

BEIJING—Hybio Pharmaceutical Co., Ltd (SHE: 300199), a Chinese biopharmaceutical company, has entered into a licensing...

Company Deals

Allist Pharmaceuticals Acquires Jacobio’s G12C Inhibitor and SHP2 Inhibitor Rights for Greater China Region

Fineline Cube Sep 2, 2024

SHANGHAI—Allist Pharmaceuticals Co., Ltd, a Shanghai-based biotech company, has entered into a licensing agreement with...

Company Deals R&D

Baheal Pharmaceutical Group to Establish R&D Center for Myocardial Repair with CAMS Fuwai Hospital

Fineline Cube Sep 2, 2024

BEIJING—Baheal Pharmaceutical Group, a leading healthcare services and distribution company in China, is venturing into...

Company Drug

Bio-Thera Solutions’ BAT2406 Biosimilar Gets Green Light for Clinical Trials in China

Fineline Cube Sep 2, 2024

GUANGZHOU—Bio-Thera Solutions (SHA: 688177), a leading biopharmaceutical company based in Guangzhou, has received approval from...

Policy / Regulatory

NMPA Unveils 82nd Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube Sep 2, 2024

The National Medical Products Administration (NMPA) has announced the release of the 82nd batch of...

Policy / Regulatory

Hainan Province Unveils Ambitious Three-Year Plan for Digital Health Innovation and Economy Expansion

Fineline Cube Sep 2, 2024

HAIKOU—The People’s Government of Hainan Province has unveiled the “Hainan Province’s Three Year Action Plan...

Policy / Regulatory

China Expands Medical Insurance Coverage to Include Assisted Reproductive Technology in 19 Regions

Fineline Cube Sep 2, 2024

BEIJING—As of September 1, 2024, a total of 19 provinces, municipalities, and the Xinjiang Production...

Company

BioAge Labs Taps Former GSK CEO Jean-Pierre Garnier as Chairman

Fineline Cube Sep 2, 2024

NEW YORK—BioAge Labs, a US-based biotechnology company specializing in anti-aging therapies, has announced the appointment...

Company Policy / Regulatory

China’s NMPA Suspends Dr. Reddy’s Atomoxetine Imports Amid Quality Concerns

Fineline Cube Sep 2, 2024

BEIJING—The National Medical Products Administration (NMPA) has issued a notification to immediately suspend the import,...

Company

Roche Diagnostics to Double Down on China with RMB 3 Billion Suzhou Plant Expansion

Fineline Cube Sep 2, 2024

SUZHOU—Roche Diagnostics, the Swiss healthcare giant, has entered into a new investment agreement with the...

Posts pagination

1 … 263 264 265 … 625

Recent updates

  • Trinomab’s Retavibart NDA Accepted by NMPA – First Long‑Acting RSV mAb for Infant Protection in China
  • Sichuan Biokin’s Iza‑Bren Hits PFS and OS Endpoints in Phase III TNBC Study – First Bispecific ADC to Show Dual Survival Benefit
  • FDA Issues Draft Guidance on Plausible Mechanism Framework – Accelerates Approval Pathway for Individualized Genetic Therapies
  • Gilead Sciences to Acquire Arcellx for $7.8B – Bolsters CAR‑T Pipeline with BCMA‑Targeted Anito‑cel
  • Pfizer Partners with Sciwind Biosciences for Ecnoglutide China Rights – $495M Deal Marks Metabolic Market Entry
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Trinomab’s Retavibart NDA Accepted by NMPA – First Long‑Acting RSV mAb for Infant Protection in China

Company Drug

Sichuan Biokin’s Iza‑Bren Hits PFS and OS Endpoints in Phase III TNBC Study – First Bispecific ADC to Show Dual Survival Benefit

Policy / Regulatory

FDA Issues Draft Guidance on Plausible Mechanism Framework – Accelerates Approval Pathway for Individualized Genetic Therapies

Company Deals

Gilead Sciences to Acquire Arcellx for $7.8B – Bolsters CAR‑T Pipeline with BCMA‑Targeted Anito‑cel

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.